Author Topic: (Abst.) Efficacy and safety of ozanimod in MS  (Read 222 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 RADIANCE trial
« on: September 08, 2019, 04:13:40 pm »

Abstract of an article in The Lancet (September 3, 2019), "Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial":

https://www.ncbi.nlm.nih.gov/pubmed/31492652
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
126 Views
Last post September 30, 2018, 07:31:15 pm
by agate
0 Replies
57 Views
Last post December 14, 2019, 04:59:16 pm
by agate
0 Replies
31 Views
Last post December 02, 2020, 03:35:02 pm
by agate
0 Replies
31 Views
Last post December 02, 2020, 03:37:34 pm
by agate
0 Replies
54 Views
Last post May 11, 2021, 09:13:10 pm
by agate